Entera Bio Ltd.

NASDAQ:ENTX

Biotechnology

Healthcare
$3.28 +0.00%

+$0.00 today

Market cap
$571.17M
Beta
1.49
P/E (TTM)
-4.6
EPS (TTM)
-$0.26
52W Low $0.91High $3.22

Volume 0.23M

Average 0.16M

Returns on capital

Entera Bio Ltd. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-87.3%

avg -67.4%

ROIC

-218.8%

avg -99.2%

ROA

-71.5%

avg -82.9%

Analysis

ROA is currently the strongest return metric at -71.5% versus its period average of -82.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Miranda J. Toledano

Chief Executive Officer & DirectorUSD 562K49——

Riccardo Paolo Camisasca

Chief Medical OfficerUSD 355K—0<0.01%

Hillel Galitzer

Chief Operating OfficerUSD 307K48200.00K0.41%

Gregory Burshtein

Chief of Research & DevelopmentUSD 254K50180.00K0.37%

Dana Yaacov-Garbeli

Chief Financial OfficerUSD 226K43140.00K0.28%

Constantin Itin

Head of Biopharmaceutics & Bioanalytics————

Michele McDermott

MD & EVP of Medical Affairs————

Rachel Wagman

Chief Clinical Advisor————

Cherin Smith

Executive Vice President & Head of Clinical Operations————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Aug 18, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

6

$121,432.20

Sells

0

$0.00

Net Transaction Value

+$121,432.20

Net buying

Most Active

Germano Geno J

2 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Mar 9, 26

Germano Geno J

Direct

Buy$26K
Mar 5, 26

Ellis Sean

Direct

Buy$12.3K
Feb 10, 26

Taitel Haya

Direct

Buy$11.1K
Feb 10, 26

Germano Geno J

Direct

Buy$29.8K
Feb 9, 26

Ellis Sean

Direct

Buy$22.3K
Dec 29, 25

Toledano Miranda Jayne

Direct

Buy$19.9K

Summary

Insiders reported 6 buys worth $121,432.20 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $121,432.20. Germano Geno J was the most active insider with 2 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/A-32.1%
+323.9% (5yr)2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Recent growth has been strongest in Revenue at -32.1% over three years. Forward estimates point to Revenue at +323.9% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Entera Bio Ltd. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about ENTX's management, answered from reported figures.

Who manages ENTX?

Entera Bio Ltd. (ENTX) lists 9 active executives. The top listed executive is Constantin Itin, Head of Biopharmaceutics & Bioanalytics.

Are ENTX insiders buying or selling?

Recent insider activity shows net buying of $11.00M.